Literature DB >> 8471312

Complement activation by gp160 glycoprotein of HIV-1.

N Thieblemont1, N Haeffner-Cavaillon, L Weiss, F Maillet, M D Kazatchkine.   

Abstract

The ability of the gp160 envelope glycoprotein of HIV-1 to activate human complement and to bind C3 fragments was investigated by incubating mammalian-derived recombinant gp160 with seronegative serum and by quantitating the binding of C3b/iC3b to the protein using a biotinylated monoclonal antibody directed against a neoepitope expressed by cleaved human C3. Recombinant gp160 activated complement in a dose- and time-dependent fashion. Complement activation occurred through the classical pathway, independently of antibodies, and required C1q. Binding of anti-HIV IgG to rgp160 prior to exposure of the envelope glycoprotein to serum resulted in enhanced complement activation. Complexes of rgp120 with anti-HIV IgG also cleaved C3 in serum, resulting in deposition of C3b on gp120. These results provide a basis for C3-mediated facilitation of viral entry into target cells expressing receptors for fragments of human C3.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8471312     DOI: 10.1089/aid.1993.9.229

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  11 in total

1.  Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis.

Authors:  W S Hlavacek; C Wofsy; A S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

2.  Mechanisms by which HIV envelope minimizes immunogenicity.

Authors:  Haixiang Jiang; Garren Hester; Larry Liao; David C Montefiori; Michael M Frank
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

3.  Contribution of follicular dendritic cells to persistent HIV viremia.

Authors:  Jingshan Zhang; Alan S Perelson
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

Review 4.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

5.  Human immunodeficiency virus-1 (HIV-1) gp120 superantigen-binding serum antibodies. A host factor in homosexual HIV-1 transmission.

Authors:  J Townsley-Fuchs; L Kam; R Fairhurst; S J Gange; L Goodglick; J V Giorgi; N Sidell; R Detels; J Braun
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

Review 6.  Enhancing role of complement in HIV infection.

Authors:  A Mouhoub; N Thieblemont; C Delibrias; E Fischer; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

Review 7.  Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions.

Authors:  N Chirmule; S Pahwa
Journal:  Microbiol Rev       Date:  1996-06

8.  Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1.

Authors:  Z Prohászka; T Hidvégi; E Ujhelyi; H Stoiber; M P Dierich; C Süsal; G Füst
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

9.  Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.

Authors:  J Schmitz; J P Zimmer; B Kluxen; S Aries; M Bögel; I Gigli; H Schmitz
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

10.  Efficacy of HIV-specific and 'antibody-independent' mechanisms for complement activation by HIV-infected cells.

Authors:  M N Saarloos; T F Lint; G T Spear
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.